Qutavina

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

teriparatide

Available from:

EuroGenerics Holdings B.V.

ATC code:

H05AA02

INN (International Name):

teriparatide

Therapeutic group:

Homeostasi tal-kalċju

Therapeutic area:

L-osteoporożi

Therapeutic indications:

Qutavina is indicated in adults. Trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Authorization status:

Irtirat

Authorization date:

2020-08-27

Patient Information leaflet

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
Prodott mediċinali li m’għadux awtorizzat
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Qutavina 20 mikrogramma/80 mikrolitri soluzzjoni għall-injezzjoni
f’ pinna mimlija lesta.
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull doża ta’ 80 mikrolitri fiha 20 mikrogramma ta’ teriparatide
*
.
Kull pinna mimlija lesta ta’ 2.7 mL fiha 675 mikrogramma ta’
teriparatide (li tikkorrispondi għal 250
mikrogramma f’ kull mL).
*
Teriparatide, rhPTH(1-34), magħmul f’
_P. fluorescens_
, permezz tat-teknoloġija rikombinanti tad-
DNA, huwa identiku għas-sekwenza ta'
_34 N-terminal amino acid _
ta’ l-ormon uman paratirodje
endoġenu.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Soluzzjoni għall-injezzjoni.
Soluzzjoni ċara u bla kulur.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Qutavina huwa indikat fl-adulti
Kura ta’ osteoporożi f’nisa wara l-menopawża u fl-irġiel li
qegħdin f’riskju ogħla ta’ ksur (ara sezzjoni
5.1). F’nisa wara l-menopawża, intwera tnaqqis sostanzjali
fl-ammont ta’ ksur vertebrali kif ukoll
f’dak mhux vertebrali iżda mhux fil-ksur ta’ l-għadma
tal-ġenbejn.
Kura ta’ osteoporożi assoċjata ma’ terapija b’glukokortikojdi
sistemiċi meħuda fit-tul, fin-nisa u fl-
irġiel li qegħdin f’riskju ogħla ta’ ksur (ara sezzjoni 5.1).
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża rakkmandata ta’ Qutavina hija 20 mikrogramma mogħtija
darba kuljum.
Il-massimu ta’ tul ta’ żmien ta’ kura b’Qutavina għandu jkun
ta’ 24 xahar (ara sezzjoni 4.4). Il-kors ta’
24 xahar ta’ Qu
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
Prodott mediċinali li m’għadux awtorizzat
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Qutavina 20 mikrogramma/80 mikrolitri soluzzjoni għall-injezzjoni
f’ pinna mimlija lesta.
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull doża ta’ 80 mikrolitri fiha 20 mikrogramma ta’ teriparatide
*
.
Kull pinna mimlija lesta ta’ 2.7 mL fiha 675 mikrogramma ta’
teriparatide (li tikkorrispondi għal 250
mikrogramma f’ kull mL).
*
Teriparatide, rhPTH(1-34), magħmul f’
_P. fluorescens_
, permezz tat-teknoloġija rikombinanti tad-
DNA, huwa identiku għas-sekwenza ta'
_34 N-terminal amino acid _
ta’ l-ormon uman paratirodje
endoġenu.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Soluzzjoni għall-injezzjoni.
Soluzzjoni ċara u bla kulur.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Qutavina huwa indikat fl-adulti
Kura ta’ osteoporożi f’nisa wara l-menopawża u fl-irġiel li
qegħdin f’riskju ogħla ta’ ksur (ara sezzjoni
5.1). F’nisa wara l-menopawża, intwera tnaqqis sostanzjali
fl-ammont ta’ ksur vertebrali kif ukoll
f’dak mhux vertebrali iżda mhux fil-ksur ta’ l-għadma
tal-ġenbejn.
Kura ta’ osteoporożi assoċjata ma’ terapija b’glukokortikojdi
sistemiċi meħuda fit-tul, fin-nisa u fl-
irġiel li qegħdin f’riskju ogħla ta’ ksur (ara sezzjoni 5.1).
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża rakkmandata ta’ Qutavina hija 20 mikrogramma mogħtija
darba kuljum.
Il-massimu ta’ tul ta’ żmien ta’ kura b’Qutavina għandu jkun
ta’ 24 xahar (ara sezzjoni 4.4). Il-kors ta’
24 xahar ta’ Qu
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-01-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-01-2021
Public Assessment Report Public Assessment Report Bulgarian 18-01-2021
Patient Information leaflet Patient Information leaflet Spanish 18-01-2021
Public Assessment Report Public Assessment Report Spanish 18-01-2021
Patient Information leaflet Patient Information leaflet Czech 18-01-2021
Public Assessment Report Public Assessment Report Czech 18-01-2021
Patient Information leaflet Patient Information leaflet Danish 18-01-2021
Public Assessment Report Public Assessment Report Danish 18-01-2021
Patient Information leaflet Patient Information leaflet German 18-01-2021
Public Assessment Report Public Assessment Report German 18-01-2021
Patient Information leaflet Patient Information leaflet Estonian 18-01-2021
Public Assessment Report Public Assessment Report Estonian 18-01-2021
Patient Information leaflet Patient Information leaflet Greek 18-01-2021
Public Assessment Report Public Assessment Report Greek 18-01-2021
Patient Information leaflet Patient Information leaflet English 18-01-2021
Public Assessment Report Public Assessment Report English 18-01-2021
Patient Information leaflet Patient Information leaflet French 18-01-2021
Public Assessment Report Public Assessment Report French 18-01-2021
Patient Information leaflet Patient Information leaflet Italian 18-01-2021
Public Assessment Report Public Assessment Report Italian 18-01-2021
Patient Information leaflet Patient Information leaflet Latvian 18-01-2021
Public Assessment Report Public Assessment Report Latvian 18-01-2021
Patient Information leaflet Patient Information leaflet Lithuanian 18-01-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-01-2021
Public Assessment Report Public Assessment Report Lithuanian 18-01-2021
Patient Information leaflet Patient Information leaflet Hungarian 18-01-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 18-01-2021
Public Assessment Report Public Assessment Report Hungarian 18-01-2021
Patient Information leaflet Patient Information leaflet Dutch 18-01-2021
Public Assessment Report Public Assessment Report Dutch 18-01-2021
Patient Information leaflet Patient Information leaflet Polish 18-01-2021
Public Assessment Report Public Assessment Report Polish 18-01-2021
Patient Information leaflet Patient Information leaflet Portuguese 18-01-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 18-01-2021
Public Assessment Report Public Assessment Report Portuguese 18-01-2021
Patient Information leaflet Patient Information leaflet Romanian 18-01-2021
Public Assessment Report Public Assessment Report Romanian 18-01-2021
Patient Information leaflet Patient Information leaflet Slovak 18-01-2021
Public Assessment Report Public Assessment Report Slovak 18-01-2021
Patient Information leaflet Patient Information leaflet Slovenian 18-01-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 18-01-2021
Public Assessment Report Public Assessment Report Slovenian 18-01-2021
Patient Information leaflet Patient Information leaflet Finnish 18-01-2021
Public Assessment Report Public Assessment Report Finnish 18-01-2021
Patient Information leaflet Patient Information leaflet Swedish 18-01-2021
Public Assessment Report Public Assessment Report Swedish 18-01-2021
Patient Information leaflet Patient Information leaflet Norwegian 18-01-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 18-01-2021
Patient Information leaflet Patient Information leaflet Icelandic 18-01-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 18-01-2021
Patient Information leaflet Patient Information leaflet Croatian 18-01-2021
Public Assessment Report Public Assessment Report Croatian 18-01-2021

Search alerts related to this product

View documents history